Navellier & Associates Increased Apple Computer (AAPL) Holding by $845,602 as Share Value Declined; David R Rahn & Associates Has Decreased Regeneron Pharmaceuticals (REGN) Holding as Stock Value Rose

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Navellier & Associates Inc increased its stake in Apple Computer Inc. (AAPL) by 113.84% based on its latest 2018Q4 regulatory filing with the SEC. Navellier & Associates Inc bought 5,386 shares as the company’s stock declined 2.81% while stock markets rallied. The hedge fund held 10,117 shares of the computer manufacturing company at the end of 2018Q4, valued at $1.60M, up from 4,731 at the end of the previous reported quarter. Navellier & Associates Inc who had been investing in Apple Computer Inc. for a number of months, seems to be bullish on the $878.44B market cap company. The stock increased 1.20% or $2.26 during the last trading session, reaching $190.92. About 26.54M shares traded. Apple Inc. (NASDAQ:AAPL) has risen 0.49% since May 16, 2018 and is uptrending. It has underperformed by 3.88% the S&P500. Some Historical AAPL News: 13/03/2018 – AMAZON IS SAID TO HAVE MULLED BUYING TEXTURE BEFORE APPLE DEAL; 27/03/2018 – TAIPEI — Many Apple suppliers and tech industry executives are voicing concerns that a trade war between the U.S. and China will not only damage their businesses but also the industry and economic growth as a result; 16/05/2018 – AppleInsider: Apple’s next iPhone may ship with more powerful USB-C charger; 25/05/2018 – A U.S. jury has ruled that Samsung should pay $539 million to Apple for copying patented smartphone features. The jury had been deliberating the latest case since last week; 18/04/2018 – MacRumors: Apple Registers Several New Unreleased iPhone Models in Eurasia Ahead of WWDC; 01/05/2018 – Puget Sound Business Journal: At Two Union, Regus is moving out to make way for a growing Apple, sources tell @MarcStilesPSBJ:; 29/05/2018 – Apple may be planning to use high-end technology in the screens for all of its new 2019 iPhone models, according to a report from South Korea’s Electronic Times; 20/03/2018 – Chicago’s New Apple Store Is Put Up for Sale; 09/04/2018 – Apple Now Globally Powered by 100 Percent Renewable Energy; 25/05/2018 – Apple has adjusted its self-driving dreams in recent years, resigning to provide the software for automaker partner Volkswagen, according to a New York Times report

David R Rahn & Associates Inc decreased its stake in Regeneron Pharmaceuticals (REGN) by 28.03% based on its latest 2018Q4 regulatory filing with the SEC. David R Rahn & Associates Inc sold 1,264 shares as the company’s stock rose 19.30% with the market. The institutional investor held 3,245 shares of the health care company at the end of 2018Q4, valued at $1.21M, down from 4,509 at the end of the previous reported quarter. David R Rahn & Associates Inc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be less bullish one the $33.39B market cap company. The stock increased 0.40% or $1.23 during the last trading session, reaching $305.85. About 784,143 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 34.82% since May 16, 2018 and is uptrending. It has outperformed by 30.45% the S&P500. Some Historical REGN News: 10/03/2018 – Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?; 10/03/2018 – REGENERON, SANOFI SAY THEY WILL MEET ICER’S RECOMMENDED PRICE; 16/05/2018 – Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with lnadequately Controlled Moderate-to-severe Atopic Dermatitis; 03/05/2018 – Regeneron Pharma 1Q Rev $1.51B; 01/05/2018 – REGENERON: EXPRESS SCRIPTS SELECTS PRALUENT EXCLUSIVE THERAPY; 16/05/2018 – DUPIXENT TRIAL MEETS PRIMARY, SECONDARY ENDPOINTS; 21/03/2018 – REGENERON & ALNYLAM: PACT TO DISCOVER NEW TREATMENTS FOR NASH; 30/04/2018 – Sanofi, Regeneron: Target Action Date for the FDA Decision Is October 28, 2018; 30/04/2018 – Sanofi, Regeneron: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma; 21/03/2018 – Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection

Investors sentiment decreased to 1.13 in Q4 2018. Its down 0.01, from 1.14 in 2018Q3. It turned negative, as 52 investors sold REGN shares while 165 reduced holdings. 72 funds opened positions while 174 raised stakes. 77.33 million shares or 9.82% more from 70.41 million shares in 2018Q3 were reported. Prentiss Smith Company accumulated 6,951 shares or 1.63% of the stock. Parallax Volatility Advisers LP stated it has 48,301 shares. Hillsdale Investment Mgmt holds 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 1,300 shares. Greenleaf Trust holds 895 shares or 0.01% of its portfolio. Moreover, North Point Portfolio Managers Oh has 2.28% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 27,676 shares. Axa holds 0.12% or 70,782 shares. Element Mgmt Lc accumulated 32,642 shares or 0.35% of the stock. Kentucky-based Central Savings Bank Trust Communications has invested 0.98% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Brinker Cap reported 0.22% stake. Piedmont Investment has invested 0.18% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). United Advisers Ltd Limited Liability Company holds 0% or 1,340 shares in its portfolio. Suntrust Banks owns 1,156 shares or 0% of their US portfolio. Citadel Lc holds 0.01% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 68,542 shares. Financial Bank Of Nova Scotia reported 16,621 shares. Livforsakringsbolaget Skandia Omsesidigt owns 676 shares.

Since December 12, 2018, it had 0 buys, and 4 insider sales for $55.44 million activity. Sanofi had sold 131,115 shares worth $54.04M. 6 shares were sold by VAGELOS P ROY, worth $2,294 on Wednesday, December 12. GOLDSTEIN JOSEPH L sold 1,791 shares worth $734,310.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “Noteworthy Friday Option Activity: REGN, T, APC – Nasdaq” on April 05, 2019, also Nasdaq.com with their article: “5 Growthy Biotech Stocks to Buy Despite the Scrutiny – Nasdaq” published on May 13, 2019, Streetinsider.com published: “Regeneron Pharma (REGN) PT Lowered to $343 at Jefferies – StreetInsider.com” on April 17, 2019. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Seekingalpha.com and their article: “Assessing If Regeneron Is In Value Territory After Shares Tumble – Seeking Alpha” published on May 08, 2019 as well as Prnewswire.com‘s news article titled: “FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization – PRNewswire” with publication date: April 26, 2019.

Navellier & Associates Inc, which manages about $2.37B and $588.17 million US Long portfolio, decreased its stake in Methanex Corp. (NASDAQ:MEOH) by 12,581 shares to 7,120 shares, valued at $343,000 in 2018Q4, according to the filing. It also reduced its holding in Moelis & Co (NYSE:MC) by 36,526 shares in the quarter, leaving it with 7,749 shares, and cut its stake in Valero Energy Corp. (NYSE:VLO).

More notable recent Apple Inc. (NASDAQ:AAPL) news were published by: Nasdaq.com which released: “Notable ETF Inflow Detected – DIA, AAPL, GS, CAT – Nasdaq” on April 30, 2019, also Seekingalpha.com with their article: “Apple: The Wall Street Quarter – Apple Inc. (NASDAQ:AAPL) – Seeking Alpha” published on May 06, 2019, Nasdaq.com published: “Better Long-Term Buy: Amazon (AMZN) vs. Apple (AAPL) Stock – Nasdaq” on May 07, 2019. More interesting news about Apple Inc. (NASDAQ:AAPL) were released by: Nasdaq.com and their article: “Nokia Stock Looks Like an interesting Contrarian Play Here – Nasdaq” published on May 15, 2019 as well as Nasdaq.com‘s news article titled: “Apple (AAPL) 2nd Quarter Earnings: What to Expect – Nasdaq” with publication date: April 30, 2019.

Investors sentiment increased to 0.97 in Q4 2018. Its up 0.30, from 0.67 in 2018Q3. It is positive, as 82 investors sold AAPL shares while 860 reduced holdings. 159 funds opened positions while 756 raised stakes. 2.83 billion shares or 5.50% more from 2.68 billion shares in 2018Q3 were reported. Bourgeon Management Ltd Limited Liability Company stated it has 1.97% of its portfolio in Apple Inc. (NASDAQ:AAPL). Stelac Advisory Services Ltd Liability Com stated it has 6,369 shares. Moreover, Cap Ltd has 0.33% invested in Apple Inc. (NASDAQ:AAPL) for 7,060 shares. Ativo Capital Ltd Liability owns 0.91% invested in Apple Inc. (NASDAQ:AAPL) for 12,341 shares. Hyman Charles D reported 93,192 shares. Employees Retirement System Of Texas has invested 1.67% in Apple Inc. (NASDAQ:AAPL). Novare Cap Limited Company invested in 2.04% or 70,848 shares. Moreover, Tirschwell Loewy Inc has 0.06% invested in Apple Inc. (NASDAQ:AAPL). Laurion Mgmt LP invested 0% of its portfolio in Apple Inc. (NASDAQ:AAPL). Iconiq Lc owns 0.62% invested in Apple Inc. (NASDAQ:AAPL) for 27,942 shares. 222,414 were accumulated by Mogy Joel R Investment Counsel. Signaturefd Llc owns 60,733 shares. Golub Gp Ltd Com holds 3.82% or 247,950 shares. Karpas Strategies Limited Liability Corporation owns 1,455 shares for 0.11% of their portfolio. Td Capital Mngmt Ltd Liability Corporation, Tennessee-based fund reported 5,088 shares.

Since November 19, 2018, it had 0 buys, and 2 selling transactions for $902,607 activity. The insider KONDO CHRIS sold $647,520.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.